Impact News +++ This biopharma stock could more than double on oral eczema treatment, Goldman Sachs says (CNBC) +++ CORVUS PHARMA Aktie -7,25%

SOLENO Aktie

>SOLENO Aktienkurs

44.525 EUR (TradegateBSX)

Ask: 44.66 EUR / 80 Stück

Bid: 44.39 EUR / 450 Stück

Tagesumsatz: 0 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

SOLENO Aktie über LYNX handeln

Intraday

1 Jahr

>SOLENO Performance

1 Woche: -0,5%

1 Monat: +53,5%

3 Monate: +21,9%

6 Monate: -23,7%

1 Jahr: -27,4%

laufendes Jahr: +10,4%

>SOLENO Aktie

Name:

SOLENO THERAPEUTICS

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US8342033094 / A3DS0P

Symbol/ Ticker:

6XC (Frankfurt) / SLNO (NASDAQ)

Kürzel:

FRA:6XC, ETR:6XC, 6XC:GR, NASDAQ:SLNO

Index:

Webseite:

https://soleno.life/

Profil:

Soleno Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for rare diseases. Its primary product, VYKAT XR (diazoxide choline extended-release tablets), is an FDA-approved once-dai..
>Volltext..

Marktkapitalisierung:

2303.82 Mio. EUR

Unternehmenswert:

2089.21 Mio. EUR

Umsatz:

161.42 Mio. EUR

EBITDA:

14.38 Mio. EUR

Nettogewinn:

17.36 Mio. EUR

Gewinn je Aktie:

0.22 EUR

Schulden:

44.55 Mio. EUR

Liquide Mittel:

59.43 Mio. EUR

Operativer Cashflow:

39.62 Mio. EUR

Bargeldquote:

4.98

Umsatzwachstum:

Gewinnwachstum:

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

2 Insider verkauften innerhalb der letzten 30 Tage Aktien im Wert von 429.345 USD.

Suchwörter:

SOLENO

Letzte Datenerhebung:

17.04.26

>SOLENO Kennzahlen

Aktien/ Unternehmen:

Aktien: 51.62 Mio. St.

Frei handelbar: 96.04%

Leerverk. Aktien: 16.37%

Rückkaufquote: -5.08%

Mitarbeiter: 182

Umsatz/Mitarb.: 0.89 Mio. EUR

Analysten:

Analystenrating: Neutral

Kursziel: 27.8%

Bewertung:

KGV: 233.48

KGV lG: 13.19

KUV: 14.89

KBV: 6.05

PEG-Ratio: -

EV/EBITDA: 145.24

Rentabilität:

Bruttomarge: 98.32%

Gewinnmarge: 10.75%

Operative Marge: 7.85%

Managementeffizenz:

Gesamtkaprendite: 4.58%

Eigenkaprendite: 5.89%

>SOLENO Peer Group

Gesundheit, Zell- & Gentherapie/ Gentechnik/ Erbkrankheiten

>SOLENO Chart & Kurs - NASDAQ

>SOLENO News

17.04.26 - 15:12	SLNO SHAREHOLDER NOTICE: Hagens Berman Alerts Soleno (SLNO) Investors to Pending Securities Fraud Class Action and Upcoming May 5th Lead Plaintiff Deadline (PR Newswire)
	SAN FRANCISCO, April 17, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman reminds investors in Soleno Therapeutics, Inc. (NASDAQ: SLNO) of the pending securities class action and the upcoming May 5, 2026 lead plaintiff deadline. The firm urges investors who......

16.04.26 - 15:06	SLNO INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026 (PR Newswire)
	Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Soleno To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Soleno between March 26, 2025 and November 4, 2025 and would like to......

15.04.26 - 21:18	Soleno Therapeutics, Inc. (SLNO) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit (PR Newswire)
	LOS ANGELES, April 15, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO) have opportunity to lead the securities fraud class action lawsuit. IF YOU ARE AN INVESTOR WHO......

15.04.26 - 20:12	INVESTOR DEADLINE: Soleno Therapeutics, Inc. (SLNO) Investors with Substantial Losses Have Opportunity to Lead the Soleno Class Action Lawsuit- Hagens Berman (PR Newswire)
	SAN FRANCISCO, April 15, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman reminds investors in Soleno Therapeutics, Inc. (NASDAQ: SLNO) of the pending securities class action and the upcoming May 5, 2026 lead plaintiff deadline. The firm urges investors who......

14.04.26 - 01:24	INVESTOR NOTICE: Soleno Therapeutics (SLNO) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action- Hagens Berman (PR Newswire)
	SAN FRANCISCO, April 13, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman reminds investors in Soleno Therapeutics, Inc. (NASDAQ: SLNO) of the pending securities class action and the upcoming May 5, 2026 lead plaintiff deadline. The firm urges investors who......

13.04.26 - 09:54	SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm (PR Newswire)
	LOS ANGELES, April 13, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Soleno Therapeutics, Inc. ("Soleno" or "the Company") (NASDAQ: SLNO) for violations of §§10(b) and 20(a) of the Securities......

13.04.26 - 09:54	Soleno Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SLNO (PR Newswire)
	LOS ANGELES, April 13, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Soleno Therapeutics, Inc. ("Soleno" or "the Company") (NASDAQ: SLNO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated......

12.04.26 - 17:57	SLNO SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026 (PR Newswire)
	Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Soleno To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Soleno between March 26, 2025 and November 4, 2025 and would like to......

11.04.26 - 04:03	Soleno Therapeutics, Inc. Notice of May 5, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline (PR Newswire)
	NEW YORK and NEW ORLEANS, April 10, 2026 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NasdaqCM: SLNO) of a class action securities......

10.04.26 - 18:36	Weekly Buzz: MacroGenics Resumes LINNET; GSK Wins China Nod; FDA Okays Waters Corporation; Neurocrine Biosciences Snaps Up Soleno Therapeutics (AFX)
	THOUSAND OAKS (dpa-AFX) - This week's biotech landscape witnessed regulatory approvals across the U.S., Canada, and China, alongside the lifting of a clinical trial hold by the FDA, collaborations......

10.04.26 - 16:24	Weekly Buzz: MGNX Resumes LINNET; GSK Wins China Nod; FDA Okays Waters; NBIX Snaps Up Soleno Therapeutics (AFX)
	THOUSAND OAKS (dpa-AFX) - This week's biotech landscape witnessed regulatory approvals across the U.S., Canada, and China, alongside the lifting of a clinical trial hold by the FDA, collaborations......

09.04.26 - 17:39	INVESTOR NOTICE: Soleno Therapeutics (SLNO) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action - Hagens Berman (PR Newswire)
	SAN FRANCISCO, April 9, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman reminds investors in Soleno Therapeutics, Inc. (NASDAQ: SLNO) of the pending securities class action and the upcoming May 5, 2026 lead plaintiff deadline. The firm urges investors who purchased......

08.04.26 - 22:24	Soleno Therapeutics, Inc. (SLNO) Investors: May 5, 2026, Deadline in Securities Fraud Class Action Lawsuit (PR Newswire)
	Did you buy SLNO common stock between March 26, 2025, and November 4, 2025? Affected Soleno Therapeutics, Inc. Investor Summary Who: Soleno Therapeutics, Inc. (NASDAQ: SLNO) What: Securities fraud class action lawsuit filed Class Period: March 26, 2025, through November 4, 2025 Deadline......

08.04.26 - 19:00	Soleno Therapeutics Stock Rallies 56.4% in a Week: Here′s Why (Zacks)
	SLNO shares surge as Neurocrine inks $2.9B cash deal to acquire it at $53 a share, adding Vykat XR and expanding its rare disease and endocrinology portfolio....

08.04.26 - 18:03	Soleno Therapeutics, Inc. (SLNO) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit (PR Newswire)
	LOS ANGELES, April 8, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO). IF YOU SUFFERED A LOSS ON YOUR......

07.04.26 - 18:25	SLNO SHAREHOLDER UPDATE: Soleno (SLNO) Facing Securities Class Action After DCCR Launch Setback, Share Drop-- Hagens Berman (PR Newswire)
	SAN FRANCISCO, April 7, 2026 /PRNewswire/ -- A securities class action lawsuit has been filed against Soleno Therapeutics, Inc. (NASDAQ: SLNO) seeking to represent investors who purchased Soleno common stock between March 26, 2025 and November 4, 2025. The lawsuit follows Soleno's......

07.04.26 - 15:02	SLNO Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Soleno Therapeutics, Inc. Securities Lawsuit -- The Gross Law Firm (PR Newswire)
	NEW YORK, April 7, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Soleno Therapeutics, Inc. (NASDAQ: SLNO). Shareholders who purchased shares of SLNO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff......

07.04.26 - 14:48	BREAKING: Für bis zu 5 Milliarden Dollar! Gilead kauft Biotech-Firma aus München (Der Aktionaer)
	Das Übernahme-Karussell im Biotech-Sektor dreht sich gefühlt von Woche zu Woche immer schneller. Erst am Ostermontag hat Neurocrine Biosciences die milliardenschwere Übernahme von Soleno Therapeutics bekanntgegeben. Am heutigen Dienstag folgt der nächste Paukenschlag: Gilead Sciences greift nach dem Münchener Biotech-Unternehmen Tubulis....

07.04.26 - 14:48	Market movers: Virgin Galactic, Soleno Therapeutics, Medicus Pharma... (Proactive Investors)
	Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...

07.04.26 - 12:24	Neurocrine to acquire Soleno in $2.9bn transaction (PBR)
	The transaction will expand Neurocrine's portfolio in endocrinology and rare diseases via the addition of Soleno's lead product, Vykat XR (diazoxide choline), for Prader-Willi syndrome (PWS). Vykat XR The post Neurocrine to acquire Soleno in $2.9bn transaction appeared first on Pharmaceutical Business review....

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Illusionen sind eine Sache, die ein Mann gleichzeitig mit seinen Haaren und Zähnen verliert. - Franziska Friedl

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram